Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (114)	11/29/2000 11:24:53 AM
From: BulbaMan	Respond to of 1784

XENO got its name in the NY Times Science section yesterday (Tuesday, 11/27/0). Below is the relevant paragraph. At 3/8, there's not much downside on XENO. DNA Chip May Help Usher in a New Era of Product Testing By ANDREW POLLACK ...Such chips are already widely used to understand the causes of disease by comparing, for example, which genes are active in cancer cells but not in healthy cells. Now companies like Affymetrix Inc., the leader in gene chips, and smaller companies like Phase-1 Molecular Toxicology of Santa Fe, N.M., and Xenometrix Inc. in Boulder, Colo., are developing specialized "tox chips" or similar test kits that contain just a subset of genes thought to be important in the response to harmful chemicals...